SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today…
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of…
Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in…
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common…
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and…
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7%…
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for…
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.